Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib/IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF)

Next Previous
Trial Profile

A phase Ib/IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perflenapent (Primary)
  • Indications COVID 2019 infections; Hypoxic respiratory failure
  • Focus Therapeutic Use
  • Sponsors NuvOx Pharma

Most Recent Events

  • 06 Jul 2020 New trial record
  • 29 Jun 2020 According to a NuvOx Pharma media release, Jarrod Mosier, MD, Associate Professor with Tenure Emergency & Internal Medicine and Associate Program Director of the Critical Care Fellowship at Banner University Medical Center, Tucson, AZ, is a Principal Investigator of the US sites in the clinical trial.
  • 29 Jun 2020 According to a NuvOx Pharma media release, Diego Martin, MD, PhD, Chairman of Radiology at McGill University, Montreal, Canada, is the Principal Investigator of the Canadian efforts on the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top